Rehovot, Israel – January 24, 2023 – Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced its CEO and VP R&D will both be participating in 7th Annual Microbiome Movement Drug Development Europe,
Rehovot, Israel – December 28, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced it will be in attendance at the Healthcare Week taking place together with the J.P. Morgan Healthcare Conference in San Francisco.
Funding round led by Shanghai Healthcare Capital
Rehovot, Israel – December 21, 2022 – Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced the signing of a definitive agreement for a $20 million financing round,
Rehovot, Israel – November 14, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced it will be participating in an Industry panel discussion at the 7th Annual Microbiome Connect USA 2022 Summit taking place between November 16-17,
This addition to Biomica’s scientific expertise will support the company’s upcoming steps in its immuno-oncology clinical development program
Rehovot, Israel – July 28, 2022 – Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
REHOVOT, Israel, July 26, 2022 – Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that the first patient was dosed in its Phase I clinical trial that is designed primarily to evaluate the safety and tolerability of Biomica’s microbiome-based immuno-oncology drug candidate,
Proof of Concept (POC) in-human trial to take place at Rambam Health Care Campus in Israel throughout 2022
REHOVOT, Israel, July 11, 2022. Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
Rehovot, Israel – July 5, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced it will be presenting at Microbiome Connect Europe taking place between July 6-7, 2022, in Amsterdam,
Dr. Elran Haber to participate in the Industry Leaders opening panel at this premier Microbiome conference
Rehovot, Israel – June 15, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics,
Rehovot, Israel – May 23, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced it will be presenting at the 2022 ASCO Annual Meeting, a conference taking place in Chicago,